Orexo Seeks FDA Approval for Opioid Dependency Drug

Swedish pharmaceutical company Orexo plans to submit OX219, a treatment for opioid dependency, for FDA approval in the U.S.

Advertisement

According to a company release, Orexo is now “on track” to seek approval following an initial consultation with the regulatory organization, which reviewed the clinical program, pre-clinical documentation and manufacturing and control plans for the drug.

Related Articles on Pain Management:

Relmada Raises $3M to Develop LevoCap Painkiller
Pain Specialist Dr. David Cheng Joins Midwest Orthopaedics
Middle Fork Surgery Center Visited by Oregon’s Co-Speaker of the House

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.